Transmissible spongiform encephalopathies are fatal neurodegenerative diseases attributed to misfolding of the cellular prion protein, PrP C , into a ␤-sheet-rich, aggregated isoform, PrP Sc . We previously found that expression of mouse PrP with the two amino acid substitutions S170N and N174T, which result in high structural order of the ␤2-␣2 loop in the NMR structure at pH 4.5 and 20°C, caused transmissible de novo prion disease in transgenic mice. Here we report that expression of mouse PrP with the single-residue substitution D167S, which also results in a structurally well ordered ␤2-␣2 loop at 20°C, elicits spontaneous PrP aggregation in vivo. Transgenic mice expressing PrP D167S developed a progressive encephalopathy characterized by abundant PrP plaque formation, spongiform change, and gliosis. These results add to the evidence that the ␤2-␣2 loop has an important role in intermolecular interactions, including that it may be a key determinant of prion protein aggregation.
Introduction
Prion diseases are infectious and invariably fatal neurodegenerative disorders caused by the conversion of cellular prion protein, PrP C , into a misfolded and aggregated isoform known as PrP Sc (Prusiner, 1982 (Prusiner, , 1998 Collinge, 2001; Deleault et al., 2007; Wang et al., 2010) . In humans, prion diseases occur in rare cases spontaneously, can be initiated by infection, or are related to inherited mutations in the prion gene, PRNP, which encodes for 208 residues in the mature polypeptide chain (Aguzzi and Calella, 2009 ). PrP C consists of a flexible, unstructured N-terminal tail and a globular C-terminal domain comprising three ␣-helices and a short ␤-sheet, and is highly conserved among mammals (Riek et al., 1996; Zahn et al., 2000; Gossert et al., 2005; Lysek et al., 2005) . Pathogenic PRNP mutations can affect all regions of the protein but display some clustering toward the C terminus (Riek et al., 1998) . Particular mutations are destabilizing, such as T183A, which eliminates two hydrogen bonds linking helix ␣2 and the ␤-sheet, yet mutations in the flexibly extended N-terminal domain do not affect stability (Riek et al., 1998) . Certain Prnp mutants in transgenic mice can reproduce PrP aggregation, clinical neurologic signs, and PrP plaques in the brain as seen in the familial diseases (Hsiao et al., 1990; Chiesa et al., 1998; Dossena et al., 2008; Jackson et al., 2009; Sigurdson et al., 2009) .
NMR spectroscopy has shown that in the solution structure at 20°C, the ␤2-␣2 loop (aa 166 -172) can be either structurally well ordered ("rigid loop," RL), or disordered (Riek et al., 1996; Gossert et al., 2005) . We previously obtained a well defined ␤2-␣2 loop structure by two amino acid exchanges in mouse PrP, S170N and N174T, and expressed the mutated Prnp gene in transgenic mice. The resulting RL mice developed a spontaneous prion disease and also showed altered susceptibility to infection by prions derived from other species (Sigurdson et al., 2009 (Sigurdson et al., , 2010 . Thus, the ␤2-␣2 loop emerges as a critical region in the PrP C structure that influences prion self-association and cross-species infections, yet the underlying molecular mechanism is incompletely understood. To further investigate how the loop topology impacts PrP aggregation in vivo, we have developed a second rigid loop transgenic mouse that expresses mouse PrP containing the singleamino acid residue substitution D167S. The horse Prnp sequence normally encodes a serine at position 167, and the NMR structures of horse PrP C and of mouse PrP C with the D167S substitution (MoPrP 167 ) both show a structurally well defined ␤2-␣2 loop in solution at ϳ20°C (Pérez et al., 2010) . We now find that overexpression of MoPrP 167 leads to widespread PrP aggregation in the brain of transgenic mice, similar to that seen in the previously studied RL mice (MoPrP 170, 174 ).
Materials and Methods

Generation of transgenic mice expressing MoPrP 167
Single-point mutations (GAT3 AGT) that alter the amino acid sequence to 167S were created within a pMECA subclone, based on pHGPrP (Fischer et al., 1996) , using the Stratagene point mutagenesis kit (primers: forward, 5Ј-GGCCA GTG AGT CAG TAC AGC AAC CAG  AAC AAC TTC GTG CAC GAC-3Ј and reverse, 5Ј-GTC GTG CAC GAA GTT GTT CTG  GTT GCT GTA CTG ACT CAC TGGCC-3Ј) . The PmeI/NheI pMECA subclone was then cloned into the PmeI/NheI sites of the pHGPrP plasmid, and the entire ORF was sequenced (Rosenberg et al., 1977) . The pHGPrP plasmid containing the mutated Prnp was propagated in Escherichia coli Top10 cells (Invitrogen), and the PrP mini-gene sequence was excised with NotI/SalI. Constructs were microinjected into the pronucleus of fertilized B6;129S5-Prnp
oocytes (Prnp-KO Zurich I) using conventional methods (Rülicke, 2004) . Founder lines were identified by PCR for the transgene using the exon-2 primer pE2ϩ (5Ј-CAA CCG AGC TGA AGC ATT CTG CCT-3Ј) and the exon-3 primer Mut217 (5Ј-CCT GGG ACT CCT TCT GGT ACC GGG TGA CGC-3Ј), and founders were bred to Prnp o/o mice. Six transgenecarrying founder mice were identified; Tg (Prnp D167S )77-82Biat. Two lines were maintained by crossing with Prnp o/o mice. To identify the KO neo-cassette, PCR analysis was performed using the primers P10 (Prnp exon 3, 5Ј-GTA CCC ATA ATC AGT GGA ACA AGC CCA GC-3Ј, 3ЈNC (non-coding region at 3Јof exon 3, 5Ј-CCC TCC CCC AGC CTA GAC CAC GA-3Ј), and P3 (neoR gene, 5Ј-ATT CGC AGC GCA TCG CCT TCT ATC GCC-3Ј); P10 and 3ЈNC gave a 560-bp signal for the Prnp ϩ allele, and P3 and 3ЈNC gave a 362-bp product for the Prnp Ϫ allele. As an alternative test for the presence or absence of the endogenous Prnp ϩ allele, an additional PCR was performed using the primers P2 (Prnp int2, 5Ј-ATA CTG GGC ACT GAT ACC TTG TTC CTC AT-3Ј) and P10rev (reverse complementary of P10 5Ј-GCT GGG CTT GTT CCA CTG ATT ATG GGT AC-3Ј), generating a 352-bp amplicon for the Prnp ϩ allele. Tga20 transgenic mice, which overexpress murine PrP (Fischer et al., 1996) , were used as controls for many of these experiments. Male and female mice were used in these studies and were maintained under specific pathogen-free conditions. This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The study protocol was approved by the University of California San Diego Institutional Animal Care and Use Committee as well as the Zü rich Cantonal Veterinary Office in Switzerland.
Western blots
Ten percent tissue homogenates were prepared in PBS using a Beadbeater tissue homogenizer. Extracts of 50 -90 g of protein were diluted in a Tris HCl-based buffer (10 mM Tris, 10 mM EDTA, 100 mM NaCl, 0.5% NP40, and 0.5% DOC) and digested with 5-50 g/ml proteinase K (PK) for 30 min at 37°C. A lithium dodecyl sulfate (LDS)-based buffer was then added, and the samples were heated to 95°C for 5 min before electrophoresis through a 12% Bis-Tris precast gel (Invitrogen), followed by transfer to a nitrocellulose membrane by wet blotting. Proteins were detected with anti-PrP antibody POM1 (epitope in the globular domain, aa 121-230) (Polymenidou et al., 2008) . For secondary detection we used an HRP-conjugated anti- mouse IgG antibody (Jackson Immunolabs) . Signals were visualized with the ECL detection kit (Pierce). Flotation assay. Brain homogenates were lysed in cold TNE buffer (25 mM Tris HCl, pH7.5, 150 mM NaCl, 5 mM EDTA, and 1% Triton X-100). Extracts were mixed with two volumes of 60% Optiprep (Nycomed) to reach a final concentration of 40%. The mixture was carefully overlaid with a 5 and 30% Optiprep step-gradient and ultracentrifuged at 100,000 ϫ g for 20 h at 4°C. Thirteen fractions were collected and used for SDS-PAGE and immunoblot analysis using anti-PrP (Pom1) and antiflotillin (Abcam) antibodies.
Detection of insoluble PrP
Brain homogenate samples were lysed in a Tris HCl-based buffer (10 mM Tris HCl, pH 8.0, 10 mM EDTA with 2% sarcosyl) and incubated at 37°C for 1 h before ultracentrifugation at 150,000 ϫ g for 1 h. Supernatant and pellet fractions were collected and treated with a nuclease (Benzonase). Supernatant proteins were concentrated by methanol precipitation before Western blotting.
Velocity sedimentation
Brain homogenates were lysed in a Tris HCl-based buffer containing 1% sarcosyl and incubated at 37°C for 10 min before layering over a 10 -54% iodixanol gradient. Dextran blue (2000 kDa) was layered over a separate gradient as a reference standard. The samples were ultracentrifuged at 200,000 ϫ g for 1 h and 175 l fractions were collected and examined by Western blotting.
PrP peptide ELISA
The peptide ELISA was performed as described by Lau et al. (2007) with minor modifications. Brain homogenate was mixed with an equal volume of lysis buffer (100 mM Tris HCl, pH 7.5, 150 mM NaCl) containing 2% sarcosyl, incubated for 10 min at 37°C, and centrifuged at 500 ϫ g to remove cell debris. The supernatant was incubated with peptide-coated magnetic beads (M-280, Invitrogen) for 1 h at 37°C with constant shaking. The beads were washed with TBS containing 0.1% Tween 20, before denaturation with 0.1 M NaOH and neutralization with 0.3 M NaH 2 PO 4 . PrP was then measured by standard sandwich ELISA using a 96-well plate precoated with 2.5 g/ml POM-2 antibody, and using a biotinylated POM-1 antibody (50 ng/ml), followed by streptavidin HRP and an Ultra TMB-ELISA substrate (Thermo Scientific) for detection. RML-infected and uninfected control brain samples were included in every experiment. Samples were run in triplicate.
Immunoprecipitation
15B3 immunoprecipitation. Samples were homogenized in Prionics buffer (Prionics, Switzerland) supplemented with protease inhibitors (1 mM PMSF and Complete TM; Roche). IgM-Dynabeads (Invitrogen) were used for preclearing the samples for 2 h at 25°C. For the immunoprecipitation (IP), the sample was added to 15B3-conjugated IgM Dynabeads and shaken at 25°C for ϳ16 h. Beads were washed and bound sample was eluted with an LDS-based sample buffer.
PrP 136 -158 IP. Brain homogenate was lysed in PBS buffer containing 1% Triton X-100 and protease inhibitors, and centrifuged at 500 ϫ g for 15 min. The supernatant was incubated with 3 g of 136 -158 antibody in 450 l of lysis buffer and shaken for 2 h at 25°C. A total of 25 l of goat anti-human (FabЈ) 2 -conjugated Dynal beads were added to each tube followed by a second round of incubation at 25°C for 16 h at 1000 rpm. The beads were washed in lysis buffer and eluted as described above. The eluted material was analyzed by SDS-PAGE, and immunoblotting was performed using the anti-PrP Pom1 antibody.
Histopathology and immunohistochemical stains
Two-m-thick sections were cut onto positively charged silanized glass slides and stained with hematoxylin and eosin, or immunostained using antibodies for PrP (SAF84), for astrocytes (GFAP), or microglia (Iba1). For PrP staining, sections were deparaffinized and incubated for 6 min in 98% formic acid. Sections were heated to 100°C in a pressure cooker or autoclaved in citrate buffer, pH 6.0, and then cooled for 3 min. Immunohistochemical stains were performed on an automated Nexus staining apparatus (Ventana Medical Systems) using an IVIEW DAB Detection Kit (Ventana). After incubation with protease 1 (Ventana) for 16 min, sections were incubated with anti-PrP SAF-84 (SPI bio; 1:200) for 32 min. Sections were counterstained with hematoxylin. GFAP immunohistochemistry for astrocytes (1:1000 for 24 min; DAKO) and Iba1 (1:2500 for 32 min; Wako Chemicals) for microglia was similarly performed, however with antigen retrieval by heating to 100°C in EDTA buffer (pH ϭ 8.0).
Luminescent conjugated polymer staining of tissue sections
The synthesis of polythiophene acetic acid (PTAA) (mean molecular weight, M W ϭ 3 kDa) has been reported (Ding et al., 2000; Ho et al., 2002) . Frozen mouse brain sections were dried for 1 h and fixed in 100% ethanol for 10 min. After washing with deionized water, the sections were equilibrated in the incubation buffer, consisting of 100 mM sodium carbonate at pH ϭ 10.2. Luminescent conjugated polymers (LCPs) were diluted in the sodium carbonate buffer (0.01 g/l), then added to the brain sections and incubated for 30 min at room temperature, and finally washed with the sodium carbonate buffer.
Fluorescence microscopy
Spectra were collected with a Zeiss Axioplan 2 microscope, fitted with a Spectraview 4.0 (Applied Spectral Imaging, Migdal, Israel) and a SpectraCube (interferometrical optical head SD 300) module with cooled CCDcamera, through a 405/30 nm (LP 450) or a 470/40 nm (LP 515) bandpass filter. The data were processed with SpectraView 3.0 EXPO. Spectra were collected from 10 individual spots within 3-5 plaques and from unstained regions and mockinoculated negative control Tga20 mice. Fluorescent spectral unmixing was performed using the function in the software.
Statistical methods
For spectral collection of PTAA bound to prion aggregates, brain sections were analyzed as follows: 10 individual spots within each of 3-5 plaques from each case were examined, yielding 30 -50 measurements per mouse. The fluorescent intensity ratios were calculated (intensity at 532 nm/emission maximum, and 532/641) and mean and SD were recorded for each spectral ratio for each individual. An unpaired, two-tailed Student's t test was performed using mean values of single animals as observations. Differences were considered statistically significant at p Ͻ 0.05 (2-tailed).
Results
Generation and characterization of MoPrP
167 transgenic mice We generated 6 founder lines of transgenic mice that express mouse PrP with a D167S substitution, which imparts a structurally well ordered ␤2-␣2 loop in the NMR solution structure determined at 20°C (Fig. 1A) , similar to that in variant mouse PrP with S170N and N174T substitutions (MoPrP 170,174 , line Tg1020) (Sigurdson et al., 2009) . To do this, we cloned the transgene into the "halfgenomic" mouse Prnp minigene (pHGPrP) containing the prion promoter and the Prnp open reading frame (Fischer et al., 1996) (Fig. 1 B) , and introduced the construct into Prnp ϩ/ Ϫ zygote pronuclei by microinjection. We bred the Tg-(MoPrP 167 ) founders to B6J;129S5 Prnp o/o mice, and quantified the PrP C expression in brain from each mouse line by Western blot and ELISA. We chose two lines, 81 and 82, which express ϳ3-to 5-fold and 1-to 2-fold PrP levels in brain when compared with WT mice, respectively (Fig. 1C) . Heart, lung, liver, stomach, spleen, and kidney were histologically normal. The highest PrP-expressing tissues in the Tg(MoPrP 167 ) mice were the CNS, skeletal muscle, and heart muscle ( Fig. 1 D) .
MoPrP 167 in young mice is biochemically and functionally indistinguishable from WT-PrP in vivo PrP
C from the Tg(MoPrP 167 ) mice was glycosylated and appeared to be processed normally (Fig. 1C) . Similar to WT PrP, MoPrP 167 was buoyant in density gradients and colocalized with flotillin, indicating residency within detergent-resistant membranes (Fig. 1 E) . Mutant PrP C functionality was assessed indirectly by crossing the Tg(MoPrP 167 ) mice with hemizygous TgF35 transgenic mice expressing amino-proximally truncated PrP(⌬32-134) (Shmerling et al., 1998; Barmada and Harris, 2005; Radovanovic et al., 2005) . TgF35 mice develop cerebellar granular cell (CGC) degeneration followed by death at 3-4 months of age, which is rescued by coexpression of wild-type MoPrP. ) mice from line 81 developed a slowly progressive neurologic disease characterized by ataxia, tremors, weight loss, kyphosis, and in some cases priapism, which was associated with striking degenerative lesions in the brain (Fig.  2 A-C) . Both diffuse and scattered PrP-immunoreactive plaques and moderate neuropil vacuolation occurred in the basal ganglia, thalamus, and cerebral cortex (Fig. 2C) . We detected intense astrogliosis and severe microglial activation in the vacuolated brain regions (Fig. 2C) , as typically seen in transmissible spongiform encephalopathies.
MoPrP
167 aggregates in the brain are labeled by LCPs The PrP aggregates in the Tg(MoPrP 167 ) mice were not stained by Congo red (Fig. 3A ), yet were stained by PTAA, which we have previously described as a new tool to distinguish prion strains (Fig. 3B) (Ding et al., 2000) . PTAA molecules interact with amyloid (Nilsson et al., 2005 and emit light with a distinct pattern of spectral intensities depending on the amyloid bound Sigurdson et al., 2007) , and may therefore serve as a surrogate marker of conformation. To compare the conformation of PTAA bound to de novo MoPrP 167 and MoPrP 170,174 aggregates, we measured the emission spectrum from PTAA labeled brain sections. We found no differences in the PTAA emission spectra between the MoPrP 167 and MoPrP 170,174 PrP aggregates (Fig. 3C) , suggesting that aggregates from mice expressing RL-PrP based on different residue substitutions have a common underlying structural feature.
Aggregated PrP in the Tg(MoPrP
) mice from line 81 is insoluble and PK sensitive
To assess whether the sarcosyl-insoluble PrP occurred in brains of the Tg(MoPrP 167 ) mice, we performed ultracentrifugation on brain homogenates from young and old Tg(MoPrP 167 ) mice, WT mice, mice infected with mouse-adapted scrapie (RML strain), and Tga20 mice, which overexpress WT mouse PrP (4-to 6-fold WT). We found that ϳ40% of the PrP was sarcosyl-insoluble in aged line 81 mice, which was significantly more than in WT (22%), lower expressing line 82 (13%), and young line 81 (23%) mice, but less than in mice infected with RML prions (62%) (Fig. 4 A) . Also, aged untreated Tga20 mice, 370 -500 d old, spontaneously showed moderate amounts of insoluble PrP (30%) (Fig. 4 A) .
Since PrP Sc in prion-infected brain is typically PK resistant, we next measured the extent to which PK-resistant PrP could be detected in the brain of Tg(MoPrP 167 ) mice. Brain homog- 167 brain homogenate using a gradient of PK concentrations at 37°C for 30 min reveals that the modified moPrP 167 is sensitive to PK at Ͼ10 g/ml PK. C, IP of PrP aggregates using a peptide-grafted antibody, 136 -158, reveals abundant PrP Sc in the immunoprecipitated fractions of RML-infected and line Tg81 (L81) mice, but not WT mice. D, Soluble and insoluble fractions were each divided for direct immunoblotting or for IP using PrP Sc -specific antibody 15B3 followed by immunoblotting using anti-PrP antibody POM1. Quantification of the percentage of pellet to total PrP Sc shows that PrP Sc is enriched in the pellet fractions after 15B3 IP (bottom), indicating that the PrP Sc is primarily insoluble. E, PrP Sc -peptide ELISA of Tg81 mice of various ages was positive in all Tg81, Tga20 and scrapie-infected mice, and negative in Tg82 mice. Prnp o/o and WT mice were used to set the upper threshold for the negative samples.
enate samples from Tg(MoPrP 167 ) and WT mice were incubated with increasing concentrations of PK. The PrP in the brain of aged Tg(MoPrP 167 ) mice was primarily PK sensitive ( Fig.  4 B) , as often seen in mice expressing mutant PrP (Hsiao et al., 1990; Jackson et al., 2009; Sigurdson et al., 2009) and in humans with certain sporadic and familial prion diseases, including fatal familial insomnia and Gerstmann-Sträussler-Scheinker disease (Medori et al., 1992; Colucci et al., 2006; Gambetti et al., 2008) .
We next determined whether the aggregates were captured by PrP Sc -specific antibodies, which may indicate conformational similarities with infectious PrP Sc . We performed immunoprecipitation using the PrP peptide 136 -158 grafted to an antibody scaffold that has been shown to bind PrP Sc (Moroncini et al., 2004) . Antibody 136 -158 immunoprecipitated abundant PrP Sc in brain from RML-infected and Tg(MoPrP 167 ) mice, but not from WT mice (Fig. 4C) . To determine whether the Tg(MoPrP
) PrP
Sc was soluble or insoluble, we performed ultracentrifugation and immunoprecipitated PrP Sc from the supernatant and pellet fractions using the PrP Sc -specific antibody 15B3 (Korth et al., 1997) (conformational epitope formed by PrP aa 142-148, 162-170, and 214 -226) . Here we found that the PrP Sc detected in the line 81 mice was primarily in the insoluble fraction, similar to RML scrapie (Fig. 4D, bottom) .
To further detect and quantify PrP Sc aggregates, we assessed whether a PrP Sc -specific peptide (aa 23-30) binds MoPrP 167 aggregates in a prion assay that excludes PK or other enzyme treatment (Lau et al., 2007) . We precipitated the PrP Sc aggregates using PrP peptide bound to magnetic beads, then denatured the bound aggregates and detected PrP by antibody ELISA. We could detect PrP aggregates in all 13 of the line 81 and scrapie-infected mice, but in none of the WT, line 82, or Prnp o/o mice. Interestingly, aggregates were also detected in the brains of all aged Tga20 mice (Fig. 4 E) , yet signals were significantly lower than in the line 81 mice exceeding 180 d of age (line Tg81 average 0.77, range 0.25-1.3; Tga20: average 0.38, range 0.20 -0.60; p ϭ 0.04, Student's t test).
PK-sensitive PrP Sc has been shown to correspond to lower density fractions after density gradient centrifugation (Pastrana et al., 2006) . To determine whether the aggregates from the Tg(MoPrP 167 ) mice were also in the lower density fractions, we measured the sedimentation properties of PrP from Tg(MoPrP 167 ), uninfected WT, Tga20 and RML-infected mice in a 10 -54% iodixanol gradient. WT PrP C was present primarily in the low density fractions 1 and 2, whereas RML was primarily in fraction 7. By comparison, the aged Tg(MoPrP 167 ) showed abundant PrP in low density fraction 4 (27%), but with a very small amount (0.5%) detected in the most dense fractions 10 and 11, which was also seen with RML. These findings indicated that most MoPrP 167 aggregates were smaller and more buoyant than RML, yet a rare dense aggregate population existed in common with RML (Fig. 5) .
Discussion
Here we show that a single-residue substitution in the ␤2-␣2 loop leads to neurodegeneration and prion plaque formation, as seen in humans with various PRNP mutations (Masters et al., 1981) . The Tg(MoPrP 167 ) and the previously described Tg (MoPrP 170, 174 ) mice are based on rationally designed modifications of mouse PrP that mimic the well defined ␤2-␣2 loop in the NMR structures at 20°C of the elk and horse prion proteins (Gossert et al., 2005; Pérez et al., 2010) . We have previously found that the mutations in the ␤2-␣2 loop of Tg(MoPrP 170,174 ) led to de novo generation of PrP plaques, spongiform degeneration, gliosis, and infectious prions in vivo (Sigurdson et al., 2009 ). Here we showed that except for its PK sensitivity, the PrP Sc in the Tg(MoPrP 167 ) mice has biochemical properties in common with mouse scrapie PrP Sc , including insolubility, recognition by conformational PrP Sc -specific antibodies and peptides, and binding by PTAA.
Several of the familial prion diseases in humans and related mouse models also develop PrP Sc with biochemical properties common to our Tg(moPrP 167 ) mice, such as PK sensitivity and insolubility (Hsiao et al., 1990; Medori et al., 1992; Colucci et al., 2006; Gambetti et al., 2008; Jackson et al., 2009; Sigurdson et al., 2009 ). Together, these data suggest that aggregates precipitated by a Prnp mutation might form different multimeric structures than those acquired by infection. In support of this hypothesis, we found that PrP aggregates from our Tg(MoPrP 167 ) mice were found primarily in lower density fractions than RML mouse PrP Sc , indicating that the aggregates may be smaller or have a different shape. Our observa- tions are consistent with previous work showing PK-sensitive PrP in lower density fractions (Pastrana et al., 2006) . It will be interesting to determine in future studies the specific aggregate size and whether this low sedimentation property occurs with additional PK-sensitive prion strains in animals and humans.
In conclusion, we now have two lines of transgenic mice expressing MoPrP with different ␤2-␣2 loop substitutions that confer RL-loop characteristics to the NMR structures at 20°C, which both develop PrP aggregates and spongiform degeneration (Sigurdson et al., 2009 ). The S170N, N174T substitutions also had a major impact on species barriers (Sigurdson et al., 2010) . Whether the increased aggregation tendency and altered species barriers are due to the altered spatial loop secondary structure, the primary sequence, or a combination of both is not yet clear. Future studies of the ␤2-␣2 loop substitutions should provide insights into the relative contribution of primary versus secondary structure of the PrP C substrate in prion assembly. The implicated key role of the ␤2-␣2 loop region in aggregation and species barriers may thus provide a starting platform for novel approaches to unravel details of the roles of wild-type prion proteins in health and disease, with possible leads into the rational design of therapies to block PrP aggregation.
